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Several hundred antimicrobial peptides (AMPs) composed of b50
amino acid residues have been discovered in plants, insects, and
vertebrates including humans, constituting host defense systems
against invading pathogenic microorganisms [1–3]. Accumulating
evidence suggests that these peptides not only directly kill pathogens
but also modulate innate immunity and even bridge the innate and
adoptive immune responses [3–6]. Many attempts have been made toGIKKFLHIIWKFIKAFVGEIMNS;
nhibitory concentration; PEG,
ll rights reserved.utilize AMPs as novel antibiotics, because they exhibit a broad
spectrum of antimicrobial activity (against Gram-positive and
negative bacteria, fungi, parasites, enveloped viruses, and even
multidrug-resistant microorganisms) and do not easily induce
resistance compared to conventional antibiotics [1,3], although they
do eventually evoke resistance [7]. Indeed, more than a dozen
companies have been commercially developing antibiotic peptides
and peptidomimetics, several of which are in clinical trials. However,
the trials are limited to topical applications, because peptides that
have apparently negligible lethality for mammalian cells in vitro are
usually toxic when injected into the bloodstream, although this issue
has not been well documented [3,8]. Systemic application would
certainly expand the usefulness of AMPs and therefore the market.
Toward this goal, toxicities associated with systemic administration
should be urgently and extensively investigated.
Fig. 1. Do AMPs really exhibit cell selectivity? (A) Magainin-induced hemolysis [17].
F5W-magainin 2 (10 μM) induces complete lysis of human erythrocytes at a cell density
of 6×105 cells/mL. Differential interference contrast images of erythrocytes before
(upper) and 40 s after (lower) addition of magainin. (B) Preferential interaction of
magainin with bacteria in the coexistence of mammalian cells (M. Zasloff, unpublished
work, with permission). A dye-labeled magainin selectively bound to Staphylococcus
aureus but not to surrounding epithelial cells.
1688 K. Matsuzaki / Biochimica et Biophysica Acta 1788 (2009) 1687–1692In this review article, I summarize the molecular basis for the cell
selectivity (bacteria versus host cells) of AMPs and various attempts to
control it. Only important original articles and recent papers are cited,
because there are a number of excellent review articles [1–3,9–13].
2. Cell selectivity of AMPs
AMPs have been ‘believed’ to exhibit cell selectivity. That is, they
selectively kill microorganisms without being signiﬁcantly toxic to
host cells. This concept, which coincides with roles of AMPs in innate
immunity, comes from a plethora of observations that AMPs are
nonhemolytic at concentrations well above their minimal inhibitory
concentrations (MICs) against various microorganisms. For example,
magainin 2 (GIGKFLHSAKKFGKAFVGEIMNS) discovered in the skin of
the African clawed frog Xenopus laevis inhibits bacterial growth in theFig. 2.Molecular basis of cell selectivity of AMPs. AMPs form amphipathic structures with a
between the positive charges of AMPs and negatively charged components (red) at the m
cellular association. Negatively charged sugar chains of glycoproteins (not shown) may also
face with the lipidic moieties of membranes (brown) also drives peptide–cell binding.concentration range 2–50 μM, whereas the concentration at which it
causes 50% hemolysis in human erythrocytes is as high as 1000 μM
[14,15]. However, this apparent cell selectivity seems to be an
experimental illusion. The conventionally used cell concentration is
completely different between antimicrobial and hemolysis assays.
Antimicrobial assays are usually carried out at a bacterial cell
concentration of 5×105 colony-forming units/mL. In contrast,
hemolysis assays are performed at hematocrit values of 1–10%,
typically 5%. Given a volume of 86 fL per erythrocyte [16], a 5%
hematocrit value corresponds to a cell concentration of 6×108 cells/
mL, which is three orders of magnitude larger than that for
antimicrobial assays. This difference is much larger on a cell surface
area basis, taking the fact that erythrocytes (∼7 μm) are bigger than
bacteria (∼1 μm) into account. It is clear that more peptides are
needed to kill more cells. Indeed, when the erythrocyte concentration
is reduced to 6×105 cells/mL, 10 μM of magainin is enough to
completely lyse cells (Fig. 1A) [17]. Furthermore, 100 μM of magainins
is enough to exert signiﬁcant cytotoxicity in mammalian cells at a
lower cell density of 0.5×104–1×105 cells/mL [18,19]. Therefore,
strictly speaking, a 100-fold difference between MICs and hemolytic
(cytotoxic) concentrations would not imply that AMPs exhibit cell
selectivity. However, one may say that AMPs are ‘practically cell-
speciﬁc’ because the hematocrit value in the blood (40–50%) is larger
than the value at which in vitro hemolysis assays are performed.
Several studies clearly showed that AMPs do exhibit cell selectivity
in actual situations. An in vitro example is shown in Fig. 1B (M. Zasloff,
unpublished work, with permission). A dye-labeled magainin selec-
tively bound to Staphylococcus aureus but not to surrounding
epithelial cells. Similarly, a human antimicrobial ubiquicidin fragment
peptide labeled with Techneitum-99m accumulated more at sites of
infection than at sites of inﬂammation in experimental animals,
although the difference was only two-fold [20]. However, it should be
stressed that AMPs are potentially toxic to mammalian cells in the
absence of microorganisms, as discussed above. Theymay be rendered
less harmful to the host simply by minimizing their interaction withpositively charged face (blue) and a hydrophobic face (brown). Electrostatic interaction
ammalian cell surface (left) and bacterial surface (right) is the major driving force for
serve as binding sites for AMPs. In addition, hydrophobic interaction of the hydrophobic
1689K. Matsuzaki / Biochimica et Biophysica Acta 1788 (2009) 1687–1692host tissues [2]. For example, epithelial cells onto which many AMPs
are secreted are relatively inert. Peptides in granules of phagocytic
leukocytes kill pathogens within phagolysosomes, thereby obviating
interaction with the extracellular milieu.
3. Molecular basis for cell selectivity
Despite their structural diversity, AMPs posses common physico-
chemical features; they are cationic and amphipathic [1,3]. The latter
property allows AMPs to favorably interact with membranes, which
are composed of amphipathic lipids (Fig. 2). Many AMPs are
considered to exert toxicity by permeabilizing the lipid matrix of
cell membranes [1,3,10], although intracellular targets have also been
suggested for certain peptides [21–23]. Even in the latter case,
peptide–membrane interaction is important for the cellular entry of
the peptide.
The cationic property of AMPs mainly contributes to cell
selectivity [10], because the surface of bacterial membranes is more
negatively charged than that of mammalian cells (Fig. 2). The cell
membranes of bacteria are rich in acidic phospholipids, such as
phosphatidylglycerol and cardiolipin [24]. As an extreme case,
phosphatidylglycerol composes ∼90% of the phospholipids in the
inner membrane of Staphylococcus epidermidis [25]. Bacteria with
higher levels of negatively charged lipids are more susceptile to
magainin [15]. The cell walls also contain anionic molecules, such as
lipopolysaccharides in the outer membrane of Gram-negative
bacteria and teichoic acids and lipoteichoic acids in the peptidoglycan
of Gram-positive bacteria.
In contrast, acidic phospholipids are usually sequestered in the
inner leaﬂets of plasma membranes in the case of mammalian cells
(Fig. 2) [26]. The outer leaﬂets are mainly composed of zwitterionic
phosphatidylcholine and sphingomyelin, although negatively charged
gangliosides are present as minor species. Recently, Lee et al. showed
that gangliosides play a pivotal role in the cellular entry of the buforin
IIb peptide (RAGLQFPVG[RLLR]3) [27].
Hydrophobic interaction between the hydrophobic face of an
amphipathic peptide and zwitterionic phospholipids on the cell
surface play a major role in the interaction of AMPs with mammalian
cell membranes. We showed using several peptides a correlation
between hemolytic activity and lytic activity against phosphatidylcho-
line liposomes [28]. This concept has been supported by a number of
biophysical studies. Hemolytic peptides exhibit strong interaction
with phosphatidylcholine, whereas nonhemolytic peptides do not (for
example, [29–36]).
Recently, anionic sulfated glycosaminoglycans, such as heparan
sulfate, have been suggested to serve as a molecular portal for the
cellular entry of Arg-rich, cell-penetrating peptides [37]. AMPs with
multiple Arg residues may be internalized via the glycosaminoglycan
pathway. Arg-lacking magainin was reported not to interact with
sulfated glycosaminoglycans [38].
Factors other than cell surface charge also contribute to cell
selectivity [28]. The presence of membrane-stabilizing cholesterol in
mammalian cells protects the cells from attack by AMPs. An inside-
negative transmembrane potential facilitates membrane permeabili-
zation probably by facilitating the insertion of positively charged
peptides into membranes. The transmembrane potential of bacterial
cells is more negative than that of normal mammalian cells [2].
As discussed in Section 2, AMPs may not exhibit cell selectivity in a
strict sense. There are several plausible explanations why. First, in the
case of bacteria, nontrivial amounts of cationic peptides are trapped
by negatively charged molecules outside the cell membrane, the
ultimate target (Fig. 2). Second, the mode of membrane permeabiliza-
tion differs between bacteria andmammalian cells. We recently found
that magainin forms a ∼3 nm pore in the Gram-positive bacterium
Bacillus megaterium, whereas it induces a huge (N23 nm) membrane
defect in Chinese hamster ovary cells [17]. Third, in contrast tobacteria, the permeabilization of plasma membranes may not be
enough for cytotoxicity against mammalian cells. The cell selectivity
issue should be seriously reinvestigated.
4. Control of cell selectivity
Various attempts have been made to improve the cell selectivity of
AMPs. These include the optimization of physicochemical parameters
of peptides, the introduction of D-amino acids, ﬂuorinated amino
acids, and unusual amino acids into peptides, the constraining of
peptide conformations, and the modiﬁcation of peptides by polymers.
4.1. Optimization of physicochemical parameters
A large family of AMPs assume cationic amphipathic helices that
are characterized by several physicochemical parameters: net charge,
helicity, hydrophobicity per residue (H), hydrophobicmoment (μ) and
the angle subtended by the positively charged polar helix face (Φ).
Generally, an increase in positive charge of up to ∼10 enhances
antimicrobial activity without signiﬁcantly affecting hemolytic activ-
ity [13]. Although many researchers have reported the structure–
activity relationships for AMPs [9,12,13], it is difﬁcult to estimate the
contributions of other parameters to antimicrobial activity and cell
selectivity, because these parameters are not necessarily independent.
The group of Dathe clariﬁed the importance of each parameter using
carefully designedmodel peptides andmagainin analogues [11,39,40].
The activity against Gram-negative bacteria is mainly determined by
charge except for inactive peptides with low hydrophobicity. In
contrast, the increase in H, μ, and Φ substantially enhances the
activity against Gram-positive bacteria and hemolytic activity.
Systematic studies by the group of Hodges [41,42] also revealed that
hemolytic activity can be signiﬁcantly decreased by simply reducing
the hydrophobicity of the helix hydrophobic face. However, peptides
with very low hydrophobicity have less antimicrobial activity. A
correlation between hydrophobicity and hemolytic activity was also
observed for cyclic peptides containing D-amino acids [43,44].
Recently, the disruption of the hydrophobic face by the introduction
of a charged residue was reported to signiﬁcantly reduce hemolytic
activity without deteriorating antimicrobial activity [36].
The hydrophobicity not only affects the cell selectivity but
also modulates the mode of peptide–membrane interaction. F5W-
magainin 2 (GIGKWLHSAKKFGKAFVGEIMNS) forms a toroidal pore
with a diameter of 2–3 nm in lipid bilayers composed of phosphati-
dylglycerol/phosphatidylcholine [45,46], whereas its analogue MG-
H1with an increased hydrophobicity (GIKKFLHIIWKFIKAFVGEIMNS,
Fig. 3) induces a larger membrane defect and the aggregation and/or
fusion of lipid vesicles [30].
In most studies, the hydrophobicity of a peptide is calculated
based on its amino acid composition. However, the hydrophobicity is
dependent on the positions of hydrophobic residues. We designed
the MG-H2 peptide (IIKKFLHSIWKFGKAFVGEIMNI, Fig. 3) with an
amino acid composition identical to that of MG-H1 [30]. Between the
two analogues, there are only two differences in the position of
substitutions, i.e. S8I and G13I versus G1I and S23I. The hydrophobic
residues are clustered in the central region of the sequence of MG-
H1, whereas they are more evenly distributed along the sequence of
MG-H2.
The other physicochemical parameters, such as the charge, H, μ,
and Φ, are almost the same in these molecules. However, the two
magainin peptides exhibited signiﬁcantly different properties. The
observed hydrophobicity (retention on a C18 column and afﬁnity for
phosphatidylcholine bilayers) of MG-H1 was much larger than that of
MG-H2 because of a tendency toward helix fraying near the termini.
MG-H1 was more hemolytic, whereas MG-H2 was more potent
against E. coli and Leishmania donovati promastigotes [47]. Thus, MG-
H2 has a larger therapeutic index.
Table 1
Examples of improvement of selective toxicity by various chemical modiﬁcations.
Peptidea MICb Hemolytic
activity
Reference
GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE-
(NH2)2
0.8–3 μM 100% at 10 μM [31]
GFFALIpKIISSPLFKTllSAVGSALSSSGGQE-
(NH2)2
0.9–6 μM ∼5% at 50 μM
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 0.3–20 μM 100% at 4 μM [32]
GIGAvLKvLTTGLPALiSWIkRKRQQ-NH2 0.8–12 μM b5% at 50 μM
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 0.5–2 μM 10% at 0.78 μM [33]
GIGAVlKVLTTGlPALISWiKRKRQQ-NH2 0.5–1 μM 10% at 6.25 μM
LKLLKKLLKKLLKLL-NH2 11–45 μg/mL 100% at
180 μg/mL
[49]
LKlLKkLlkKLLkLL-NH2 5.6 μg/mL 0% at 180 μg/mL
KWKKLLKKLLKLLKKLLK-NH2 4–8 μM 55% at 25 μM [54]
KWKKLLKKALKLAKKLLK-NH2 1–4 μM 0% at 100 μM
VRRFPWWWPFLRR-NH2 1–8 μM 70% at 200 μM [56]
VRRFKWWWKFLRR-NH2 1–4 μM 0% at 200 μM
CH3-S-CKLLLKWLLKLLKC-S-CH3 2–150 μM 100% at 10 μM [35]
C⁎KLLLKWLLKLLKC⁎ 1–30 μM 50% at 50 μM
C⁎KllLKWLlKlLKC⁎ 1–20 μM b10% at 50 μM
a Underlined letters indicate peptoid residues. Lower case letters indicate D-amino
acids. Cysteine residues with asterisks are connected by a disulﬁde bond.
b Range of minimum inhibitory concentrations against several microorganisms
tested.
Fig. 3. Position-dependent hydrophobicity of magainin peptides [30,47]. Helical wheel
(above) and helical net (middle) representations of the magainin analogs MG-H1 (left)
and MG-H2 (right). The shaded areas indicate the polar surface of the amphipathic
helix. The hydrophobicity of each amino acid is represented by a gray scale with the
most polar residues in black. Physicochemical properties and biological activities of the
peptides are also summarized (bottom).
1690 K. Matsuzaki / Biochimica et Biophysica Acta 1788 (2009) 1687–16924.2. Introduction of D-amino acids and ﬂuorinated amino acids
Introduction of amino acids with the opposite chirality in the
hydrophobic face of amphipathic secondary structures breaks the
secondary structures, reducing hydrophobic interaction necessary for
interaction with mammalian cells (Table 1). The substitution of
several amino acid residues in hemolytic peptides with correspond-
ing D-amino acids was found to improve selective toxicity. Shai and
Oren replaced P7, L18, and L19 in a cytolytic paradaxin peptide with
their D-counter parts. The hemolytic activity was reduced depending
on the number of D-amino acids introduced, with the triple
substituted analog practically nonhemolytic, whereas the attenua-
tion of antimicrobial activity was within two-fold [31]. A similar
strategy was used to increase the therapeutic index of bee venom
melittin [32,33], synthetic amphipathic peptides mainly composed of
K and L [34,48], and cyclic gramicidin S analogs [44]. Notably, this
approach also signiﬁcantly improves the in vivo efﬁcacy of the
intravenously administered amphipathic peptide LKLLKKLLKKLLKLL-
NH2 [49].
Attempts to use enantiomeric peptides solely composed of D-
amino acids have also been made to enhance the therapeutic index.
The enantiomer of the 13-mer peptide pEM-2 (KKWRWWLKALAKK)
reduced the endotoxin-induced lethality in mice, whereas the all L
peptide exhibited no effect [50]. This effect can be explained by the
fact that peptides containing D-amino acids are resistant to proteolysis
[51,52].
Meng and Kumar recently found that the susceptibility of AMPs to
proteolysis can be reduced by incorporating ﬂuorinated amino acids[53]. The substitution of 5, 5, 5, 5′, 5′, 5′-2S-hexaﬂuoroleucine residues
for two Leu residues in buforin peptides reduced the rate of peptide
degradation by trypsin by ca. 50%. Furthermore, this modiﬁcation
enhanced antimicrobial activity without augmenting hemolytic
activity. However, this strategy did not work for magainin. The
hemolytic activity was increased without improving antimicrobial
activity, and the susceptibility to trypsin was not changed.
4.3. Introduction of peptoid residues
Asmentioned above, breaking secondary structures by introducing
D-amino acids in the hydrophobic faces of amphiphilic peptides is a
promising strategy to improve cell selectivity. The introduction of
peptoid residues (N-substituted glycines) has also been reported to
increase the therapeutic index. The secondary structures are disrupted
because of the lack of a hydrogen atom attached to a nitrogen atom
capable of forming a hydrogen bond, similarly to Pro. The original
work by the group of Shin discovered that the substitution of Ala-
peptoid residues for L9 and L13 of the α-helical KLW peptide
(KWKKLLKKLLKLLKKLLK-amide) signiﬁcantly reduced hemolytic and
cytotoxic activities without weakening antimicrobial activity (Table 1)
[54]. Interestingly, this substitution also changed the mode of action
from membrane disruption to DNA binding. Similar approaches were
used to enhance the selective toxicity of cathelicidin-derived Trp/Pro-
rich peptides [55,56] and melittin [57]. In addition to peptides
containing a few peptoid residues, peptide mimetics composed of
peptoid residues [58–60] and α-peptide/β-peptoid chimeras [61]
have been examined as alternatives to AMPs.
4.4. Cyclization
The cyclization of linear peptides was found to increase selective
toxicity. Oren and Shai cyclized the linear AMP CKLLLKWLLKLLKCwith
an intramolecular disulﬁde bond (Table 1) [35]. The parent peptide
was strongly active against Gram-positive bacteria and highly
hemolytic. The cyclic peptide exhibited stronger antimicrobial activity
even toward Gram-negative bacteria and signiﬁcantly weaker hemo-
lytic activity than the linear peptide, although the cyclization did not
change the helical structure of the peptide in negatively charged
membranes as evaluated by infrared spectroscopy. A combination of
cyclization with D-amino acid substitution further enhanced the
1691K. Matsuzaki / Biochimica et Biophysica Acta 1788 (2009) 1687–1692therapeutic index by almost nullifying the hemolytic activity. The
cyclization method was successfully applied also to a melittin
analogue [62]. Cyclization not only enhances selective toxicity but
also increases protease stability. The half-life of a cyclic analog of the
U-shaped indolicidin peptide analogue CP-11 in the presence of
trypsin was increased by 4.5 fold [63].
However, this approach is not universal. Although cyclization
eventually increased the therapeutic index, cyclization of the
hexapeptide RRWWRF increased both antimicrobial and hemolytic
activity with the former more signiﬁcantly increased [64]. In contrast,
the cyclization of a magainin analogue reduced both antimicrobial and
hemolytic activity [62].
4.5. PEGylation
Attaching a polyethyleneglycol (PEG) moiety to peptide and
protein drugs (PEGylation) is frequently used to improve the in vivo
efﬁcacy of these drugs [65]. The pioneering work by Guiotto et al.
reported that PEGylation reduced the antimicrobial activity of nisin by
more than two fold, although solubility was improved [66]. We
investigated the effects of PEGylation of α-helical magainin 2 [19] and
tachyplesin I having a cyclic β-sheet structure [67]. The attachment of
a large PEG moiety (5 kDa) at the N-terminus reduced the membrane
binding for both peptides. A reduction in membrane-permeabilizing
activity occurred only for magainin, because the PEGylation destabi-
lized the secondary structure. The structure of tachyplesin I was not
affected by the PEGylation because it is stabilized by two disulﬁde
bonds. Interestingly, the PEGylation did not change the essential mode
of action against lipid bilayers. The PEGylation signiﬁcantly reduced
cytotoxicity and antimicrobial activity at the same time. The extent of
the decrease depended on the peptide. The antimicrobial activity of
magainin 2 was lowered only by 4-fold, whereas that of tachyplesin I
was reduced much more. Optimization of the size of the PEG moiety
may improve the therapeutic index of AMPs.
5. Conclusion
I would stress again that the dogma that AMPs exhibit cell
selectivity should be reconsidered in a strict sense, because it
originates from an experimental illusion. However, AMPs are
practically cell-selective, and a great number of studies focused on
the improvement of cell selectivity of AMPs were in the right
direction. The results suggest that strong antimicrobial activity and
less cytotoxicity can be achieved by increasing the net positive charge
of the peptide with minimal hydrophobicity above a threshold. This is
consistent with the hypothesis that the lipid composition of cell
surfaces primarily determines cell selectivity. The hydrophobicity
effectively responsible for cytotoxicity is that on the hydrophobic face
of the amphipathic secondary structure formed upon binding to the
membrane. Residues close to the ends of a helix do not fully contribute
to the effective hydrophobicity. A reduction in hydrophobicity can be
achieved by introducing charged residues, D-amino acids, or peptoid
residues into the hydrophobic face or by cyclization of the peptide.
Each method has pros and cons. The use of enantiomeric or unusual
amino acids contributes to resistance to proteolytic degradation,
however, it has a problem in biotechnological production. Further-
more, plausible in vivo toxicity is of deep concern. Conversely, AMPs
exclusively with natural amino acids are suitable for mass production,
but proteolysis is inevitable.
Despite extensive research, knowledge on the interaction of AMPs
with mammalian cells is still very limited. Most researchers employ
hemolytic assays as a measure of cytotoxicity. However, erythrocytes
are specialized cells without extracellular matrices or intracellular
organella. Studies using mammalian cell lines have examined only cell
viability. More subtle toxicities and the mode of AMP–cell interaction
should be urgently investigated.Acknowledgement
This work was supported in part by a Grant-in-aid for Scientiﬁc
Research (20659005) from JSPS.
References
[1] M. Zasloff, Antimicrobial peptides of multicellular organisms, Nature 415 (2002)
389–395.
[2] M.R. Yeaman, N.Y. Yount, Mechanisms of antimicrobial peptide action and
resistance, Pharmacol. Rev. 55 (2003) 27–55.
[3] R.E.W. Hancock, H.-G. Sahl, Antimicrobial and host-defense peptides as new anti-
infective therapeutic strategies, Nat. Biotechnol. 24 (2006) 1551–1557.
[4] K.L. Brown, R.E.W. H., Cationic host defense (antimicrobial) peptides, Curr. Opin.
Immunol. 18 (2006) 24–30.
[5] N. Mookherjee, R.E.W. Hancock, Cationic host defence peptides: innate immune
regulatory peptides as a novel approach for treating infections, Cell Mol. Life Sci.
64 (2007) 922–933.
[6] R.P. Allaker, Host defence peptides—a bridge between the innate and adaptive
immune responses, Trans. R. Soc. Trop. Med. Hyg. 102 (2008) 3–4.
[7] G.G. Perron, M. Zasloff, G. B., Experimental evolution of resistance to an
antimicrobial peptide, Proc. Biol. Sci. 273 (2006) 251–256.
[8] L. Zhang, S.M. Harris, T.J. Falla, in: R.L. Gallo (Ed.), Antimicrobial Peptides in
Human Health and Disease, Horizon Bioscience, Norfolk, 2005, pp. 331–360.
[9] W.L. Maloy, U.P. Kari, Structure–activity studies on magainins and other host
defense peptides, Biopolymers 37 (1995) 105–122.
[10] K. Matsuzaki, Why and how are peptide–lipid interactions utilized for self-
defence? Magainins and tachyplesins as archetypes, Biochim. Biophys. Acta 1462
(1999) 1–10.
[11] M. Dathe, T. Wieprecht, Structural features of helical antimicrobial peptides: their
potential to modulate activity on model membranes and biological cells, Biochim.
Biophys. Acta 1462 (1999) 71–87.
[12] A. Tossi, L. Sandri, A. Giangaspero, Amphipathic, α-helical antimicrobial peptides,
Biopolymers 55 (2000) 4–30.
[13] I. Zelezetsky, A. Tossi, Alpha-helical antimicrobial peptides—using a sequence
template to guide structure–activity relationship studies, Biochim. Biophys. Acta
1758 (2006) 1436–1449.
[14] M. Zasloff, Magainins, a class of antimicrobial peptides from Xenopus skin:
isolation, characterization of two active forms, and partial cDNA sequence of a
precursor, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5449–5453.
[15] K. Matsuzaki, K. Sugishita, M. Harada, N. Fujii, K. Miyajima, Interactions of an
antimicrobial peptide, magainin 2, with outer and inner membranes of gram-
negative bacteria, Biochim. Biophys. Acta 1327 (1997) 119–130.
[16] M.P. Westerman, L.E. Pierce, W.N. Jensen, A direct method for the quantitative
measurement of red cell dimensions, J. Lab. Clin. Med. 57 (1961) 819–824.
[17] Y. Imura, N. Choda, K. Matsuzaki, Magainin 2 in action: distinct modes of
membrane permeabilization in living bacterial and mammalian cells, Biophys. J.
(2008) in press.
[18] K. Takeshima, A. Chikushi, K.-K. Lee, S. Yonehara, K. Matsuzaki, Translocation of
analogues of the antimicrobial peptides magainin and buforin across human cell
membranes, J. Biol. Chem. 278 (2003) 1310–1315.
[19] Y. Imura, M. Nishida, K. Matsuzaki, Action mechanism of PEGylated magainin 2
analogue peptide, Biochim. Biophys. Acta 1768 (2007) 2578–2585.
[20] G. Ferro-Flores, C. Arteaga deMurphy,M. Pedraza-López, L. Meléndez-Alafort, Y.M.
Zhang, M. Rusckowski, D.J. Hnatowich, In vitro and in vivo assessment of 99mTc-
UBI speciﬁcity for bacteria, Nucl. Med. Biol. 30 (2003) 597–603.
[21] C.B. Park, H.S. Kim, S.C. Kim, Mechanism of action of the antimicrobial peptide
buforin II: buforin II kills microorganisms by penetrating the cell membrane and
inhibiting cellular functions, Biochem. Biophys. Res. Commun. 244 (1998)
253–257.
[22] C. Subbalakshmi, N. Sitaram, Mechanism of antimicrobial action of indolicidin,
FEMS Microbiol. Lett. 160 (1998) 91–96.
[23] G. Kragol, S. Lovas, G. Varadi, B.A. Condie, R. Hoffmann, L. Otvos Jr., The
antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and
prevents chaperone-assisted protein folding, Biochemistry 40 (2001) 3016–3026.
[24] C. Ratledge, S.G. Wilkinson, Microbial Lipids, vol. 1, Academic Press, London 1988.
[25] P. Komaratat, M. Kates, The lipid composition of a halotolerant species of
Staphylococcus epidermidis, Biochim. Biophys. Acta 398 (1975) 464–484.
[26] A.J. Verkleij, R.F.A. Zwaal, B. Roelofsen, P. Comfurius, D. Kastelijn, L.L.M.V. Deenen,
The asymmetric distribution of phospholipids in the human red cell membrane. A
combined study using phospholipases and freeze-etch electron microscopy,
Biochim. Biophys. Acta 323 (1973) 178–193.
[27] H.S. Lee, C.B. Park, J.M. Kim, S.A. Jang, I.Y. Park, M.S. Kim, J.H. Cho, S.C. Kim,
Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide,
Cancer Lett. 271 (2008) 47–55.
[28] K. Matsuzaki, K. Sugishita, N. Fujii, K. Miyajima, Molecular basis for membrane
selectivity of an antimicrobial peptide, magainin 2, Biochemistry 34 (1995)
3423–3429.
[29] M. Dathe, M. Schümann, T. Wieprecht, A. Winkler, K. Matsuzaki, O. Murase, M.
Beyermann, E. Krause, M. Bienert, Peptide helicity and membrane surface charge
modulate the balance of electrostatic and hydrophobic interactions with lipid
bilayers and biological membranes, Biochemistry 35 (1996) 12612–12622.
[30] T. Tachi, R.F. Epand, R.M. Epand, K. Matsuzaki, Position-dependent hydrophobicity
of the antimicrobial magainin peptide affects the mode of peptide–lipid
interactions and selective toxicity. Biochemistry 41 (2002) 10723–10731.
1692 K. Matsuzaki / Biochimica et Biophysica Acta 1788 (2009) 1687–1692[31] Y. Shai, Z. Oren, Diastereoisomers of cytolysins, a novel class of potent antibacterial
peptides, J. Biol. Chem. 271 (1996) 7305–7308.
[32] Z. Oren, Y. Shai, Selective lysis of bacteria but not mammalian cells by
diastereomers of melittin: structure–function study, Biochemistry 36 (1997)
1826–1835.
[33] W.L. Zhu, Y.H. Nan, K.S. Hahm, S.Y. Shin, Cell selectivity of an antimicrobial
peptide melittin diastereomer with D-amino acid in the leucine zipper sequence,
J. Biochem. Mol. Biol. 40 (2007) 1090–1094.
[34] Z. Oren, J. Hong, Y. Shai, A repertoire of novel antibacterial diastereomeric peptides
with selective cytolytic activity, J. Biol. Chem. 272 (1997) 14643–14649.
[35] Z. Oren, Y. Shai, Cyclization of a cytolytic amphipathic α-helical peptide and its
diastereomer: effect on structure, interaction with model membranes, and
biological function, Biochemistry 39 (2000) 6103–6114.
[36] A. Hawrani, R.A. Howe, T.R. Walsh, C.E. Dempsey, Origin of low mammalian
cell toxicity in a class of highly active antimicrobial amphipathic α-helical peptides,
J. Biol. Chem. 283 (2008) 18636–18645.
[37] G.M.K. Poon, J. Gariépy, Cell-surface proteoglycans asmolecular portals for cationic
peptide and polymer entry into cells, Biochem. Soc. Trans. 35 (2007) 788–793.
[38] G. Klocek, J. Seelig, Melittin interaction with sulfated cell surface sugars,
Biochemistry 47 (2008) 2841–2849.
[39] T. Wieprecht, M. Dathe, M. Schümann, E. Krause, M. Beyermann, M. Bienert,
Conformational and functional study of magainin 2 in model membrane
environments using the new approach of systematic double-D-amino acid
replacement, Biochemistry 35 (1996) 10844–10853.
[40] T. Wieprecht, M. Dathe, M. Beyermann, E. Krause, W.L. Maloy, D.L. MacDonald, M.
Bienert, Peptide hydrophobicity controls the activity and selectivity of magainin 2
amide in interaction with membranes, Biochemistry 36 (1997) 6124–6132.
[41] Y. Chen, C.T. Mant, S.W. Farmer, R.E.W. Hancock, M.L. Vasil, R.S. Hodges, Rational
design of alpha-helical antimicrobial peptides with enhanced activities and
speciﬁcity/therapeutic index, J. Biol. Chem. 280 (2005) 12316–12329.
[42] Y. Chen, M.T. Guarnieri, A.I. Vasil, M.L. Vasil, C.T. Mant, R.S. Hodges, Role of peptide
hydrophobicity in the mechanism of action of alpha-helical antimicrobial
peptides, Antimicrob. Agents Chemother. 51 (2007) 1398–1406.
[43] L.H. Kondejewski, M. Jelokhani-Niaraki, S.W. Farmer, B. Lix, C.M. Kay, B.D. Sykes,
R.E.W. Hancock, R.S. Hodges, Dissociation of antimicrobial and hemolytic activities
in cyclic peptide diastereomers by systematic alterations in amphipathicity, J. Biol.
Chem. 274 (1999) 13181–13192.
[44] D.L. Lee, J.P. Powers, K. Pﬂegerl, M.L. Vasil, R.E.W. Hancock, R.S. Hodges, Effects of
single D-amino acid substitutions on disruption of β-sheet structure and
hydrophobicity in cyclic 14-residue antimicrobial peptide analogs related to
gramicidin S, J. Pept. Res. 63 (2004) 69–84.
[45] K. Matsuzaki, O. Murase, N. Fujii, K. Miyajima, An antimicrobial peptide, magainin
2, induced rapid ﬂip-ﬂop of phospholipids coupled with pore formation and
peptide translocation, Biochemistry 35 (1996) 11361–11368.
[46] S.J. Ludtke, K. He, W.T. Heller, T.A. Harroun, L. Yang, H.W. Huang, Membrane pores
induced by magainin, Biochemistry 35 (1996) 13723–13728.
[47] E. Guerrero, J.M. Saugar, K. Matsuzaki, L. Rivas, Role of positional hydrophobicity in
the leishmanicidal activity of magainin 2, Antimicrob. Agents Chemother. 48
(2004) 2980–2986.
[48] J. Hong, Z. Oren, Y. Shai, Structure and organization of hemolytic and
nonhemolytic diastereomers of antimicrobial peptides in membranes, Biochem-
istry 38 (1999) 16963–16973.
[49] A. Braunstein, N. Papo, Y. Shai, In vitro activity and potency of an intravenously
injected antimicrobial peptide and its DL amino acid analog in mice infected with
bacteria. Antimicrob. Agents Chemother. 48 (2004) 3127–3129.[50] C. Santamaría, S. Larios, S. Quirós, J. Pizarro-Cerda, J.P. Gorvel, B. Lomonte, E.
Moreno, Bactericidal and antiendotoxic properties of short cationic peptides
derived from a snake venom Lys49 phospholipase A2, Antimicrob. Agents
Chemother. 49 (2005) 1340–1345.
[51] K. Hamamoto, Y. Kida, Y. Zhang, T. Shimizu, K. Kuwano, Antimicrobial activity and
stability to proteolysis of small linear cationic peptides with D-amino acid
substitutions, Microbiol. Immunol. 46 (2002) 741–749.
[52] Y. Chen, A.I. Vasil, L. Rehaume, C.T. Mant, J.L. Burns, M.L. Vasil, R.E.W. Hancock, R.S.
Hodges, Comparison of biophysical and biologic properties of alpha-helical
enantiomeric antimicrobial peptides, Chem. Biol. Drug Des. 67 (2006) 162–173.
[53] H. Meng, K. Kumar, Antimicrobial activity and protease stability of peptides
containing ﬂuorinated amino acids, J. Am. Chem. Soc. 129 (2007) 15615–15922.
[54] Y.M. Song, Y. Park, S.S. Lim, S.T. Yang, E.R. Woo, I.S. Park, J.S. Lee, J.I. Kim, K.S. Hahm,
Y. Kim, S.Y. Shin, Cell selectivity and mechanism of action of antimicrobial model
peptides containing peptoid residues, Biochemistry 44 (2005) 12094–12106.
[55] W.L. Zhu, K.S. Hahm, S.Y. Shin, Cathelicidin-derived Trp/Pro-rich antimicrobial
peptides with lysine peptoid residue (Nlys): therapeutic index and plausible
mode of action, J. Pept. Sci. 13 (2007) 529–535.
[56] W.L. Zhu, H. Lan, Y. Park, S.T. Yang, J.I. Kim, I.S. Park, H.J. You, J.S. Lee, Y.S. Park, Y.
Kim, K.S. Hahm, S.Y. Shin, Effects of Pro → peptoid residue substitution on cell
selectivity and mechanism of antibacterial action of tritrpticin-amide antimicro-
bial peptide, Biochemistry 45 (2006) 13007–13017.
[57] W.L. Zhu, Y.M. Song, Y. Park, K.H. Park, S.T. Yang, J.I. Kim, I.S. Park, K.S. Hahm, S.Y.
Shin, Substitution of the leucine zipper sequence in melittinwith peptoid residues
affects self-association, cell selectivity, and mode of action, Biochim. Biophys. Acta
1768 (2007) 1506–1517.
[58] B. Goodson, A. Ehrhardt, S. Ng, J. Nuss, K. Johnson, M. Giedlin, R. Yamamoto, W.H.
Moos, A. Krebber, M. Ladner, M.B. Giacona, C. Vitt, J. Winter, Characterization
of novel antimicrobial peptoids, Antimicrob Agents Chemother. 43 (1999)
1429–1434.
[59] J.A. Patch, A.E. Barron, Helical peptoid mimics of magainin-2 amide, J. Am. Chem.
Soc. 125 (2003) 12092–12093.
[60] N.P. Chongsiriwatana, J.A. Patch, A.M. Czyzewski, M.T. Dohm, A. Ivankin, D.
Gidalevitz, R.N. Zuckermann, A.E. Barron, Peptoids that mimic the structure,
function, and mechanism of helical antimicrobial peptides, Proc. Natl. Acad. Sci.
U. S. A. 105 (2008) 2794–2799.
[61] C.A. Olsen, G. Bonke, L. Vedel, A. Adsersen, M. Witt, H. Franzyk, J.W. Jaroszewski,
alpha-Peptide/beta-peptoid chimeras, Org. Lett. 9 (9) 1549–1552.
[62] T. Unger, Z. Oren, Y. Shai, The effect of cyclization of magainin 2 and melittin
analogues on structure, function, and model membrane interactions: implication
to their mode of action, Biochemistry 40 (2001) 6388–6397.
[63] A. Rozek, J.P. Powers, C.L. Friedrich, R.E.W. Hancock, Structure-based design of an
indolicidin peptide analogue with increased protease stability, Biochemistry 42
(2003) 14130–14138.
[64] M. Dathe, H. Nikolenko, J. Klose, M. Bienert, Cyclization increases the antimicrobial
activity and selectivity of arginine- and tryptophan-containing hexapeptides,
Biochemistry 43 (2004) 9140–9150.
[65] J.M. Harris, R.B. Chess, Effect of PEGylation on pharmaceuticals, Nat. Rev., Drug
Discov. 2 (2003) 214–221.
[66] A. Guiotto, M. Pozzobon, M. Canevari, R. Manganelli, M. Scarin, F.M. Veronese,
PEGylation of the antimicrobial peptide nisin A: problems and perspectives,
Farmaco 58 (2003) 45–50.
[67] Y. Imura, M. Nishida, Y. Ogawa, Y. Takakura, K. Matsuzaki, Action mechanism of
tachyplesin I and effects of PEGylation, Biochim. Biophys. Acta 1768 (2007)
1160–1169.
